AOD-9604

Overview

AOD-9604 (Anti-Obesity Drug 9604) is a 16-amino acid peptide derived from the C-terminal fragment of human growth hormone (GH). It consists of amino acids 176-191 of the GH molecule with a tyrosine residue appended. The peptide was developed by Metabolic Pharmaceuticals Limited, an Australian pharmaceutical company, based on decades of research examining the lipolytic (fat-burning) properties of growth hormone.

AOD-9604 was designed with a specific therapeutic rationale: growth hormone is known to promote lipolysis (fat breakdown) and inhibit lipogenesis (fat synthesis), but full-length GH also has undesirable effects including growth promotion (problematic in adults), potential diabetes risk through effects on glucose metabolism, and mitogenic (growth-promoting) effects on tissues. The theoretical advantage of AOD-9604 is that the C-terminal fragment might retain the fat-metabolizing properties of GH while avoiding these growth-promoting side effects.

Metabolic Pharmaceuticals advanced AOD-9604 into human clinical trials, including Phase 2 efficacy studies for obesity. However, in 2007, AOD-9604 failed its Phase 2 clinical trial primary endpoint-it did not demonstrate statistically significant weight loss compared to placebo. This represents a critical fact: despite preclinical promise, AOD-9604 failed to prove efficacy in humans when tested in a controlled clinical trial.

As of April 2026, AOD-9604 has no FDA approval as a drug. However, it has obtained GRAS (Generally Recognized As Safe) status from the FDA-but this status is specifically for use as a food ingredient, not as a pharmaceutical. This distinction is important and often misunderstood. AOD-9604 remains studied in research settings and discussed in anti-obesity and peptide research communities, despite its failed clinical trial history.

FDA and Regulatory Status

As of April 2026:

• NOT FDA-approved as a drug for any medical indication
• Phase 2 clinical trial FAILED primary endpoint for obesity (2007)
• GRAS status from FDA,but only for food ingredient use, not pharmaceutical use
• No active clinical trials on ClinicalTrials.gov for therapeutic development
• Not approved internationally: EU, UK, Canada, Australia, or Japan as a pharmaceutical
• No pharmaceutical company is currently developing AOD-9604 for therapeutic use

The failure of AOD-9604's Phase 2 clinical trial is the most important regulatory fact. Clinical trial failure typically ends commercial development of a pharmaceutical candidate. That AOD-9604 has a GRAS status for food ingredients is irrelevant to its efficacy as a therapeutic agent for obesity or weight loss.

The Phase 2 Clinical Trial Failure: What Happened?

The Trial Design and Execution

Metabolic Pharmaceuticals conducted Phase 2 clinical trials of AOD-9604 for obesity in the early to mid-2000s. These were randomized, controlled trials examining whether AOD-9604 treatment would produce statistically significant weight loss compared to placebo in obese subjects. The trials were adequately designed and powered to detect therapeutic effects if they existed.

The Primary Endpoint Failure

The Phase 2 trial did not meet its primary endpoint. AOD-9604 treatment did not produce statistically significant weight loss compared to placebo. This is not a matter of interpretation-a compound either does or does not achieve its pre-specified primary endpoint in a clinical trial. AOD-9604 did not.

Implications of Trial Failure

In pharmaceutical development, a Phase 2 efficacy failure typically results in termination of clinical development. Companies do not continue investing in compounds that fail to demonstrate efficacy in human trials, as the risk of further development without evidence of benefit is unjustifiable. The fact that AOD-9604 was not advanced to Phase 3 trials reflects this standard industry response to Phase 2 failure.

Why Was Development Not Pursued?

AOD-9604 did not progress to Phase 3 trials because it failed to demonstrate efficacy in Phase 2. No amount of preclinical data or theoretical mechanism justifies investing in Phase 3 trials-which are expensive, lengthy, and require demonstrated Phase 2 efficacy as justification. The absence of Phase 3 trials is entirely consistent with AOD-9604's failed Phase 2 results.

Preclinical Promise vs. Clinical Reality

AOD-9604 represents a classic example of the gap between preclinical promise and clinical reality. The peptide showed theoretical promise based on the lipolytic properties of the GH fragment, and this likely generated the preclinical data supporting initial clinical investigation. However, when tested in humans, it failed to produce weight loss. This is not unusual-many preclinical findings fail to translate to human efficacy. It highlights the critical importance of human clinical trials in determining whether a compound actually works in people.

Mechanism of Action: The Growth Hormone Fragment Hypothesis

AOD-9604's theoretical mechanism is based on decades of research on growth hormone and its lipolytic properties. The following represents the proposed mechanism:

The GH Lipolytic Fragment Discovery

Growth hormone (GH) has multiple biological effects mediated by different receptors and signaling pathways. Full-length GH activates the GH receptor, which has both metabolic effects (fat mobilization, increased lipolysis) and growth/mitogenic effects (increased protein synthesis, bone growth, organ growth). Research in the 1990s identified that the C-terminal fragment of GH (amino acids 176-191) retained lipolytic activity without the growth-promoting properties of full GH.

Lipolysis Without Growth-Promoting Effects

AOD-9604 was designed to recapitulate this lipolytic fragment activity. The theoretical advantages are: (1) stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat synthesis); (2) no growth hormone receptor activation (avoiding growth-promoting effects); (3) no effects on IGF-1 (insulin-like growth factor-1, which mediates many GH growth effects); and (4) no adverse effects on blood glucose or insulin sensitivity (avoiding the diabetogenic potential of GH).

Mechanism Details (Proposed)

AOD-9604 is theorized to stimulate lipolysis in adipose tissue through mechanisms that remain incompletely characterized. Unlike full GH, which works through the GH receptor, the C-terminal fragment may act through a different receptor or pathway. The specific receptor and signaling cascade activated by AOD-9604 have not been definitively established. Some research suggests effects on adipocyte metabolism through β-adrenergic or other signaling pathways.

Why the Mechanism Matters-and Why It Doesn't

A detailed understanding of AOD-9604's mechanism would be scientifically interesting. However, it is irrelevant to the primary clinical question: Does AOD-9604 produce weight loss in humans with obesity? The Phase 2 trial answered this question: it does not (at least not statistically significantly compared to placebo). The theoretical mechanism, no matter how elegant, cannot overcome a failed efficacy trial.

Preclinical Research and Animal Studies

Before entering clinical trials, AOD-9604 was extensively studied in preclinical models. The preclinical evidence supported lipolytic effects:

In Vitro Studies

Cell culture studies demonstrated that AOD-9604 stimulates lipolysis (breakdown of stored triglycerides) and inhibits lipogenesis (synthesis of new fat) in cultured adipocytes. These findings provided the scientific rationale for pursuing clinical development.

Animal Studies

Studies in rodent obesity models reported that AOD-9604 administration resulted in reductions in body weight and body fat mass. These results appeared promising and justified advancement to human clinical trials. However, as is frequently the case, animal efficacy did not translate to human efficacy.

The Preclinical-Clinical Translation Problem

AOD-9604's failure in humans despite preclinical success exemplifies why human clinical trials are essential. Obesity in humans is a complex, multifactorial condition involving genetics, nutrition, physical activity, metabolic adaptation, and numerous physiological systems. Animal models of obesity, while useful for understanding mechanisms, may not accurately predict human responses. Preclinical efficacy in rodent models does not guarantee human efficacy.

Dosing Protocols: Phase 2 Trial and Research Discussion

Phase 2 Clinical Trial Dosing

In the Phase 2 clinical trial, Metabolic Pharmaceuticals tested AOD-9604 at doses of 250-500 mcg daily administered via subcutaneous injection. Subjects were randomized to active treatment or placebo and followed for efficacy endpoints (weight loss). Despite these doses, AOD-9604 did not achieve statistical significance for weight loss compared to placebo.

Preclinical Dosing in Research

In animal research, preclinical doses varied but typically ranged from lower doses (that showed some efficacy in rodents) to the doses eventually tested in Phase 2 human trials. The selection of Phase 2 human doses (250-500 mcg daily) was based on preclinical data and dose-escalation considerations.

Why the Phase 2 Doses Failed

Several possibilities could explain why the doses that showed some efficacy in animal models failed in humans: (1) the mechanism of action may be species-specific and not translate to humans; (2) human obesity may have compensatory mechanisms that prevent the lipolytic effects of AOD-9604 from producing net weight loss; (3) human metabolic adaptation may override acute lipolytic effects; or (4) the doses were simply ineffective in humans, despite theoretical predictions.

Clinical Outcome: The Phase 2 trial failure indicates that these doses (and presumably any dose of AOD-9604) were not effective for weight loss in humans with obesity.

Side Effects and Safety Profile

Safety Advantages

As designed, AOD-9604 did not affect blood glucose or IGF-1 levels, avoiding the metabolic side effects of full growth hormone. No serious adverse events were documented in Phase 2 trials.

Long-Term Safety Unknown

The Phase 2 trial provided safety data over weeks to a few months only. Long-term safety data does not exist.

The GRAS Status Misconception: Food Ingredient vs. Drug Approval

AOD-9604's GRAS (Generally Recognized As Safe) status is frequently misunderstood or misrepresented in discussions about the peptide. This section clarifies the distinction:

What is GRAS Status?

GRAS stands for "Generally Recognized As Safe" under the Federal Food, Drug, and Cosmetic Act. GRAS status is an FDA food safety determination indicating that a substance is safe to use as a food ingredient. It is not a pharmaceutical approval. GRAS determination is based on expert consensus that the substance is safe for food use, typically at expected dietary exposure levels.

AOD-9604's GRAS Status

AOD-9604 obtained GRAS status, meaning the FDA does not object to its use as a food ingredient at certain levels. This was a food safety decision, not a therapeutic efficacy decision.

GRAS Does NOT Mean Drug Approval

A substance can have GRAS status as a food ingredient while having no pharmaceutical approval as a drug. These are two entirely separate regulatory pathways with different criteria. GRAS status indicates food safety. It does not indicate therapeutic efficacy, is not equivalent to a drug approval, and does not mean the FDA has determined the substance to be safe or effective as a therapeutic agent.

Common Misrepresentation

Unfortunately, AOD-9604's GRAS status is sometimes cited in discussions about the peptide as if it represents FDA validation or approval. This is misleading. The GRAS status is completely separate from the clinical trial failure. AOD-9604 can have GRAS food ingredient status while simultaneously having failed its efficacy trial as a pharmaceutical.

What GRAS Does and Does Not Imply

GRAS implies: The substance is safe to add to foods as an ingredient, in typical food consumption amounts. GRAS does NOT imply: The substance has therapeutic efficacy for any disease or condition; the substance is approved as a drug; the substance has been proven effective through clinical trials; or the substance is appropriate for injection or other pharmaceutical administration routes.

AOD-9604: GRAS Food Ingredient, Failed Drug

AOD-9604 is correctly described as: a GRAS food ingredient (approved for food use) and a failed clinical drug candidate (failed Phase 2 efficacy trial for obesity). Both statements are true and neither contradicts the other. They exist in different regulatory domains.

Comparison to Other Fat Loss Peptides

AOD-9604 is frequently discussed alongside other peptides in anti-obesity and weight loss research contexts. The following provides context:

AOD-9604 vs. Tesamorelin

Tesamorelin is a GH-releasing hormone analog that was FDA-approved specifically for lipodystrophy (abnormal fat distribution) in HIV/AIDS patients. Unlike AOD-9604, tesamorelin actually completed Phase 3 trials and achieved FDA approval, albeit for a narrow indication. Tesamorelin's approval status reflects successful clinical trials, in contrast to AOD-9604's failed Phase 2.

AOD-9604 vs. GLP-1 Receptor Agonists

More recently, GLP-1 receptor agonists (semaglutide, tirzepatide) have been FDA-approved for weight loss and have demonstrated substantial efficacy in clinical trials. These represent genuine breakthroughs in obesity pharmacotherapy based on proven clinical efficacy. AOD-9604, which failed to achieve efficacy in its Phase 2 trial, stands in sharp contrast.

AOD-9604 in the Context of Obesity Therapeutics

The obesity pharmaceutical landscape has evolved significantly since AOD-9604 was abandoned. Current FDA-approved options include GLP-1 agonists with proven substantial efficacy. AOD-9604's failed clinical trial is increasingly irrelevant in modern obesity treatment discussions, as more effective options now exist with demonstrated clinical efficacy.

Stacking Considerations

In research community discussions, AOD-9604 is sometimes discussed as part of broader metabolic or body-composition-optimization protocols, often combined with other lipolytic, thermogenic, or metabolic-support peptides. The theoretical premise is that AOD-9604's selective fat-reduction mechanism could be complemented by agents that enhance energy expenditure, suppress appetite, or improve metabolic efficiency. However, no published human studies have examined the safety or efficacy of AOD-9604 combined with other peptides or compounds.

Commonly Discussed Research Combinations

Reported protocols in research contexts sometimes describe AOD-9604 stacked with agents such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide), thermogenic peptides, metabolic-support peptides like MOTS-C or NAD+ precursors, or other lipotropic compounds. The theoretical rationale is that concurrent action on fat metabolism (AOD-9604), energy expenditure (thermogenic agents), and cellular energy production (metabolic peptides) might produce synergistic body-composition improvements. Other discussions involve combining AOD-9604 with skin-health peptides like GHK-Cu in anti-aging contexts, based on the idea that fat reduction combined with collagen support creates a more complete aesthetic improvement. These combinations remain entirely speculative, based on mechanistic theory rather than human evidence.

Pharmacological and Safety Concerns

Combining multiple metabolic-modulating agents introduces unknown risks: excessive lipolysis, metabolic dysregulation, additive effects on energy production, potential cardiovascular stress, and unknown drug-drug interactions. The fact that AOD-9604 itself failed to demonstrate meaningful clinical benefit in Phase II trials (as reviewed above) suggests that simple combinations with other agents are unlikely to overcome its fundamental limitations.

Evidence Status: No published human studies have examined AOD-9604 combined with other peptides or metabolic agents. All reported stacking discussions represent theoretical extrapolations without clinical evidence of safety or efficacy.

Frequently Asked Questions